WO2024047394 - COMBINATION THERAPIES FOR TREATMENT OF T-CELL LYMPHOMAS WITH TOLINAPANT, CEDAZURIDINE AND DECITABINE
National phase entry is expected:
Publication Number
WO/2024/047394
Publication Date
07.03.2024
International Application No.
PCT/IB2022/060652
International Filing Date
04.11.2022
Title **
[English]
COMBINATION THERAPIES FOR TREATMENT OF T-CELL LYMPHOMAS WITH TOLINAPANT, CEDAZURIDINE AND DECITABINE
[French]
POLYTHÉRAPIES POUR LE TRAITEMENT DE LYMPHOMES À LYMPHOCYTES T AVEC TOLINAPANT, CÉDAZURIDINE ET DÉCITABINE
Applicants **
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors
SIMS, Martin John
WARD, George Albert
KEER, Harold
OGANESIAN, Aram
Priority Data
63/374,137
31.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3270 | |
| EPO | Filing, Examination, Granting | 32781 | |
| Japan | Filing, Examination, Granting | 3430 | |
| South Korea | Filing, Examination, Granting | 4497 | |
| USA | Filing, Examination, Granting | 12340 |
Total:
56,318
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates generally to methods of treating T-cell lymphomas with combination therapies.[French]
La présente divulgation concerne de manière générale des méthodes de traitement de lymphomes à lymphocytes T avec des polythérapies.